Abstracts Archive - Page 977 of 2607 - ACR Meeting Abstracts

Abstract Number: 045 • 2020 Pediatric Rheumatology Symposium
No-Shows: a Search for Modifiable Risk Factors
Samantha Ong ¹, Xujia Li ¹ and Austin Dalrymple², ¹Saint Louis University School of Medicine, St. Louis, ²Saint Louis University School of Medicine, Saint Louis, Missouri
Background/Purpose: Missed ambulatory visits, or “no-shows,” limit patient access, increase costs, occupy provider time, and lead to worse patient outcomes. Only a few studies have…
Abstract Number: 046 • 2020 Pediatric Rheumatology Symposium
Near Infrared Indocyanine Green Imaging Reveals Altered Anatomy and Diminished Function in Lymphatic Vessels in the Hands of Rheumatoid Arthritis Patients During Flare
Richard Bell ¹, Homaira Rahimi², H. Mark Kenney ², Ronald Wood ², Alicia Lieberman ³, Edward Schwarz ⁴ and Christopher Ritchlin ⁵, ¹University of Rochester Medical Center, Rochester, ²University of Rochester, Rochester, ³Batavia, ⁴University of Rochester, Rochester, NY, USA, Rochester, ⁵University of Rochester Medical Center, Canandaigua
Background/Purpose: Near infrared (NIR) imaging studies of subdermal indocyanine green (ICG) in murine models of inflammatory arthritis have established abnormal lymphatic vessel (LV) function during…
Abstract Number: 047 • 2020 Pediatric Rheumatology Symposium
Patients with Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry: Clinical Characteristics and Inception Cohorts
Yongdong Zhao¹, Timothy Beukelman ², Yukiko Kimura ³, Mara Becker ⁴, Sarah Ringold ⁵, Anne Dennos ⁶ and Laura Schanberg ⁷ for the CARRA investigators, ¹University of Washington, Seattle, ²University of Alabama at Birmingham, Birmingham, ³Hackensack Meridian School of Medicine, Hackensack, ⁴Duke University Medical Center/Duke Clinical Research Institute, Chapel Hill, ⁵Seattle Children's, Seattle, ⁶Duke University, Durham, ⁷Duke University Hospital, DURHAM
Background/Purpose: In July 2015, the CARRA Registry was re-established as a multi-center observational study that collects essential data from patients with childhood-onset rheumatic diseases. The…
Abstract Number: 048 • 2020 Pediatric Rheumatology Symposium
Novel Algorithm to Increase Sensitivity of Detecting Active Arthritis in Children Through Infrared Thermal Imaging
Yongdong Zhao¹, Ramesh Iyer ¹, Mahesh Thapa ¹, Debosmita Biswas ¹, Kevin Cain ¹, Savannah Partridge ¹ and Carol Wallace ¹, ¹University of Washington, Seattle
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children. The use of infrared thermal imaging for screening JIA has not utilized…
Abstract Number: 049 • 2020 Pediatric Rheumatology Symposium
Levels of Anxiety and Depressive Symptoms in Juvenile Idiopathic Arthritis (JIA) and Their Correlation to Disease Manifestations Using Patient-Reported Outcomes Measurement Information System (PROMIS®) Measures
Danielle Fair¹, Judyann Olson ², Jan Lemke ³, Stella Protopapas ⁴, Ke Yan ⁵ and Jian Zhang ⁶, ¹Medical College of Wisconsin & Affiliated Hospitals: Children's Wisconsin, Wauwatosa, Wisconsin, ²Medical College of Wisconsin: Children's Wisconsin, Wauwatosa, Wisconsin, ³Children's Wisconsin, Milwaukee, Wisconsin, ⁴Riley Children’s Hospital at Indiana University, Indianapolis, Indiana, ⁵Medical College of Wisconsin, Milwaukee, Wisconsin, ⁶Medical College of Wisconsin, 53226, Wisconsin
Background/Purpose: Children with chronic diseases have higher rates of mental health issues and less favorable outcomes than the general pediatric population. Children with JIA experience…
Abstract Number: 050 • 2020 Pediatric Rheumatology Symposium
Long Term Safety of Biologics and Biosimilars in Pediatric Rheumatic Diseases: An Experience from a Single North Indian Centre
MANJARI AGARWAL ¹, Sujata Sawhney² and Anju Singh ³, ¹Sir Ganga Ram Hospital, NEW DELHI, Delhi, India, ²Sir ganga ram hospital, Sector 37 noida, Uttar Pradesh, India, ³Sir Ganga Ram Hospital, delhi, India
Background/Purpose: The use of biologic response modifiers(BRMs) is associated with an increased risk of infections.We also use biosimilars for two reasons:1. originator not available, like…
Abstract Number: 051 • 2020 Pediatric Rheumatology Symposium
Pediatric Providers’ Perspectives on Suspected Immune-Mediated Diffuse Alveolar Hemorrhage and Clinical Care Pathways
Jessica Bloom¹ and Robert Fuhlbrigge ², ¹Children's Hospital Colorado, Aurora, Colorado, ²University of Colorado, Aurora
Background/Purpose: Immune-mediated diffuse alveolar hemorrhage (iDAH) is a life-threatening complication of pediatric rheumatologic diseases such as vasculitis, systemic lupus erythematosus, and antiphospholipid antibody syndrome. Delay…
Abstract Number: 052 • 2020 Pediatric Rheumatology Symposium
Nasopharyngeal Pneumococcus Colonization in Patients with Childhood Onset Systemic Lupus Erythematosus (cSLE) Compared to Healthy Controls
Fatima Barbar-Smiley¹, Stacy Ardoin ², Chack-Yung Yu ³, Veronica Mruk ⁴, Cagri Yildirim-Toruner ², Vidya Sivaraman ⁵, Joanne Drew ¹, alexa meara ⁶, Asuncion Mejias ² and Octavio Ramilo ⁷, ¹Nationwide Children's Hospital, Columbus, Ohio, ²Nationwide Children's Hospital, Columbus, ³Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, ⁴The Ohio State University, Columbus, ⁵Division of Rheumatology, Nationwide Children's Hospital, Bexley, ⁶The Ohio State University Wexner Medical Center, COLUMBUS, ⁷Nationwide Children's Hospital, 700 Children's Drive
Background/Purpose: Streptococcus pneumoniae (S. pneumoniae) may lead to severe life-threatening infections in both the general and immunocompromised population. Patients diagnosed with Systemic Lupus Erythematosus (SLE)…
Abstract Number: 053 • 2020 Pediatric Rheumatology Symposium
Acceptability and Usability Testing of a Preliminary Version of the JIA Option Map, an Electronic Decision Aid for Pain Management Options in Juvenile Idiopathic Arthritis
Karine Toupin April¹, Adam Huber ², Ciaran Duffy ³, Deema Couchman ¹, Laurie Proulx ⁴, Esi Morgan ⁵, Fjolla Berbatovci ¹, Andrea Boyd ¹, Hannah Sachs ¹, Alexandra Sirois ⁶, Lucie Brosseau ³, Janice Cohen ⁷, Margaret Bisch ³, Aditi Sivakumar ¹, Marco Ragusa ¹, Tania El Hindi ⁸, Isabelle Gaboury ⁹, Linda Li ¹⁰, Elizabeth Stringer ¹¹, France Legare ¹², Sabrina Cavallo ¹³, Michele Gibbon ¹⁴, Paul Fortin ¹⁵, William Brinkman ⁵, Mark Connelly ¹⁶, Jennifer Weiss ¹⁷, Sabrina Gmuca ¹⁸, Peter Tugwell ¹⁹ and Jennifer Stinson ²⁰, ¹Children's Hospital of Eastern Ontario Research Institute, Ottawa, Canada, ²IWK Health Centre & Dalhousie University, Halifax, Nova Scotia, Canada, ³Ottawa, Canada, ⁴Canadian Arthritis Patient Alliance, Ottawa, Canada, ⁵Cincinnati Children's Hospital, Cincinnati, ⁶Outremont, Canada, ⁷Children's Hospital of Eastern Ontario, Ottawa, Canada, ⁸Statistics Canada, Ottawa, Canada, ⁹University of Sherbrooke, Sherbrooke, Canada, ¹⁰University of British Columbia, Vancouver, Canada, ¹¹IWK Health Centre, Halifax, Canada, ¹²Laval University, Quebec City, Canada, ¹³University of Montreal, Montreal, Canada, ¹⁴Children's Hospital of Eastern Ontario RI, Ottawa, Canada, ¹⁵CHU de Quebec - Universite Laval, Quebec, Canada, ¹⁶Kansas City, ¹⁷Hackensack University Medical Center, Hackensack, ¹⁸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, ¹⁹University of Ottawa - Ottawa, Ottawa, Canada, ²⁰University of Toronto & The Hospital for Sick Children, Toronto, Ontario, Canada
Background/Purpose: Although juvenile idiopathic arthritis (JIA) is one of the most common causes of chronic musculoskeletal pain among youth, families’ decision-making for pain management is…
Abstract Number: 054 • 2020 Pediatric Rheumatology Symposium
Clinical and Laboratory Characteristics in Juvenile-onset Systemic Lupus Erythematosus Across Age Groups
Joseph Massias ¹, Eve Smith ¹, Michael Beresford ¹ and Christian Hedrich¹, ¹University of Liverpool, Liverpool, United Kingdom
Background/Purpose: Systemic lupus erythematous (SLE) is a systemic autoimmune/inflammatory condition. Up to 20% of patients develop symptoms before their 18th birthday and are diagnosed with…
Abstract Number: 055 • 2020 Pediatric Rheumatology Symposium
Differential Analysis of Serum and Urine S100 Proteins in Juvenile-onset Systemic Lupus Erythematosus (jSLE)
Sean Donohue ¹, Angela Midgley ¹, Jennifer Davies ¹, Rachael Wright ¹, Ian Bruce ², Michael Beresford ¹ and Christian Hedrich¹, ¹University of Liverpool, Liverpool, United Kingdom, ²The University of Manchester, Manchester, United Kingdom
Background/Purpose: Juvenile-onset systemic lupus erythematosus (jSLE) is a systemic autoimmune/inflammatory disease. Up to 80% of patients develop lupus nephritis (LN) that affects treatment and prognosis(1-3).…
Abstract Number: 056 • 2020 Pediatric Rheumatology Symposium
Non-criteria Antiphospholipid Antibodies Associated with Pediatric Rheumatic Disease: A Single-Center Case Series
Shawn Mahmud¹, Danielle Bullock ¹, Colleen Correll ¹, Patricia Hobday ², Mona Riskalla ³, Richard Vehe ⁴ and Bryce Binstadt ¹, ¹University of Minnesota, Minneapolis, ²Minneapolis, ³University of Minnesota, Minneapolis, Minnesota, ⁴University of Minnesota, Roseville
Background/Purpose: Non-criteria antiphospholipid antibodies (NC-aPL) bind molecules such as phosphatidylethanolamine (PE), phosphatidylserine (PS), and prothrombin (Pt), but not the targets of routine antiphospholipid (aPL) testing…
Abstract Number: 057 • 2020 Pediatric Rheumatology Symposium
Transition from Pediatric to Adult Rheumatology: The Clinician as a Fundamental Ally
Teresa Semalulu ¹, Karen Beattie ¹, Jeanine McColl ¹, Arzoo Alam ², Steffy Thomas ¹, Julie Herrington ³, Jan Willem Gorter ¹, Tania Cellucci ¹, Stephanie Garner ¹, Liane Heale ⁴, Mark Matsos ¹ and Michelle Batthish¹, ¹McMaster University, Hamilton, Canada, ²McMaster University, Mississauga, Canada, ³Hamilton, Canada, ⁴McMaster University, Toronto, Canada
Background/Purpose: The transition from pediatric to adult rheumatology is linked to poor outcomes in the absence of comprehensive transition programs. Several tools are available to…
Abstract Number: 058 • 2020 Pediatric Rheumatology Symposium
Kawasaki Disease in Ontario Children from 1995-2017: A Population-based Descriptive Analysis
Cal Robinson ¹, Rahul Chanchlani ¹, Megan Schlorff ¹, Francis Lao ¹, Tapas Mondal ¹, Catherine Demers ¹, Elizabeth Darling ¹, Sandeep Brar ², Rulan Parekh ³, Hsien Seow ¹, Eric Benchimol ⁴ and Michelle Batthish¹, ¹McMaster University, Hamilton, Canada, ²University of California, San Fransisco, ³University of Toronto, Toronto, Canada, ⁴University of Ottawa, Ottawa, Canada
Background/Purpose: Kawasaki disease (KD) is a childhood vasculitis with rising global incidence and the most common cause of childhood acquired heart disease in the developed…
Abstract Number: 059 • 2020 Pediatric Rheumatology Symposium
Challenges Faced by Families of Children with an Auto-inflammatory Disease
Lori Tucker¹, Maria Belen ², Jenny Tekano ², Iwona Niemietz ³, Martina Sundqvist ³ and Kelly Brown ³, ¹BC Children's Hospital, Vancouver, British Columbia, Canada, ²BC CHildren's Hospital, Vancouver, Canada, ³BC Children's Hospital Research Institute, Vancouver, Canada
Background/Purpose: Auto-inflammatory diseases (AIDs) are rare disorders that usually present in young children. Disease episodes, characterized by recurrent inflammation, are often frequent and unpredictable, and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].